INCB123667 + bevacizumab

INCB123667 + bevacizumab is an investigational combination therapy under clinical evaluation for advanced or metastatic solid tumors, particularly for advanced gynecologic malignancies such as ovarian cancer. **INCB123667** is a small-molecule, selective inhibitor of cyclin-dependent kinase 2 (**CDK2**), a key cell cycle regulator implicated in tumor cell proliferation, especially in tumors with cyclin E1 overexpression or CCNE1 amplification. The addition of **bevacizumab**, an anti-vascular endothelial growth factor A (**VEGFA**) monoclonal antibody that inhibits angiogenesis, aims to enhance antitumor efficacy by targeting both tumor cell cycling and the tumor vasculature. The combination is being assessed in ongoing phase 1 and phase 2 clinical trials for safety, preliminary efficacy, and tolerability in patients with platinum-resistant or refractory ovarian cancer and other selected solid tumors[3][5][7].